Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Agios Pharmaceuticals Inc's Business Segments
Agios Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Product revenue net
Total Revenue
$ 45
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product revenue net46.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product revenue net | $ 21 | 46.4% |
Revenue by Product & Service Category - FY
- Product100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 21 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product revenue net46.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product revenue net | $ 21 | 46.4% |
Description of Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc. is a biopharmaceutical company that primarily focuses on the discovery, development, and commercialization of medicines to treat genetic and metabolic diseases. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts, United States.
Agios Pharmaceuticals operates with a mission to change the lives of patients by delivering innovative therapies that target the underlying causes of diseases. They aim to transform the treatment landscape for RARS-T, PK deficiency, Thalassemia, and other rare genetic diseases. Additionally, the company is dedicated to developing medicines for cancer patients with metabolic derangements as well as diseases associated with mitochondrial function and red blood cell metabolism.
One of the foundational elements of the company's research and development efforts is its expertise in cellular metabolism. Agios Pharmaceuticals has pioneered the understanding of cellular metabolism and how it can be targeted to treat diseases. They have developed a proprietary platform called Cellular Metabolism Analysis Platform (CMAP) which helps in the identification of novel targets and therapies.
The company has a robust pipeline of potential medicines spanning multiple disease areas. Their lead product candidate, Idhifa (enasidenib), is a targeted therapy for patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Idhifa has received regulatory approvals in the United States and European Union.
In addition to Idhifa, Agios Pharmaceuticals has a number of clinical-stage pipeline candidates. These include mitapivat, a potential treatment for patients with pyruvate kinase (PK) deficiency, and ivosidenib, a targeted therapy for patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation.
The company has also entered into strategic collaborations with leading pharmaceutical companies to further its research and development efforts. Agios has collaborations with Celgene, CStone Pharmaceuticals, and CytomX Therapeutics, among others.
Agios Pharmaceuticals has a strong commitment to scientific innovation, evidenced by its numerous patents and scientific publications. They have a dedicated team of scientists, researchers, and professionals with deep expertise in various fields, including biology, chemistry, and translational medicine.
Furthermore, Agios Pharmaceuticals is actively involved in giving back to the community through initiatives that foster health and education. They support several organizations and programs focused on patient advocacy, disease awareness, and scientific research.
In summary, Agios Pharmaceuticals Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for genetic and metabolic diseases. With a strong pipeline of potential treatments, a focus on cellular metabolism, and strategic collaborations, the company aims to revolutionize healthcare and improve the lives of patients worldwide.
Agios Pharmaceuticals operates with a mission to change the lives of patients by delivering innovative therapies that target the underlying causes of diseases. They aim to transform the treatment landscape for RARS-T, PK deficiency, Thalassemia, and other rare genetic diseases. Additionally, the company is dedicated to developing medicines for cancer patients with metabolic derangements as well as diseases associated with mitochondrial function and red blood cell metabolism.
One of the foundational elements of the company's research and development efforts is its expertise in cellular metabolism. Agios Pharmaceuticals has pioneered the understanding of cellular metabolism and how it can be targeted to treat diseases. They have developed a proprietary platform called Cellular Metabolism Analysis Platform (CMAP) which helps in the identification of novel targets and therapies.
The company has a robust pipeline of potential medicines spanning multiple disease areas. Their lead product candidate, Idhifa (enasidenib), is a targeted therapy for patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Idhifa has received regulatory approvals in the United States and European Union.
In addition to Idhifa, Agios Pharmaceuticals has a number of clinical-stage pipeline candidates. These include mitapivat, a potential treatment for patients with pyruvate kinase (PK) deficiency, and ivosidenib, a targeted therapy for patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation.
The company has also entered into strategic collaborations with leading pharmaceutical companies to further its research and development efforts. Agios has collaborations with Celgene, CStone Pharmaceuticals, and CytomX Therapeutics, among others.
Agios Pharmaceuticals has a strong commitment to scientific innovation, evidenced by its numerous patents and scientific publications. They have a dedicated team of scientists, researchers, and professionals with deep expertise in various fields, including biology, chemistry, and translational medicine.
Furthermore, Agios Pharmaceuticals is actively involved in giving back to the community through initiatives that foster health and education. They support several organizations and programs focused on patient advocacy, disease awareness, and scientific research.
In summary, Agios Pharmaceuticals Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for genetic and metabolic diseases. With a strong pipeline of potential treatments, a focus on cellular metabolism, and strategic collaborations, the company aims to revolutionize healthcare and improve the lives of patients worldwide.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing potential therapies for rare genetic diseases and cancer. The companys efforts are primarily centered around its innovative drug discovery platform and its commitment to advancing metabolic therapies.
Segments
1. Rare Genetic Diseases:
- Agios has a significant focus on rare genetic disorders, particularly those related to alterations in cellular metabolism. These disorders often require specialized treatments that target the underlying metabolic pathways. The companys pipeline includes therapies specifically aimed at treating conditions like pyruvate kinase deficiency (PK deficiency), which is a rare hereditary disease causing hemolytic anemia.
2. Oncology:
- The oncology segment involves the development of therapies aimed at various types of cancer. Agios is deeply invested in understanding the metabolic processes that drive cancer cell growth and survival, leading to the creation of targeted therapies that can selectively inhibit specific metabolic pathways that support tumor growth.
Products
1. Elahere (mirvetuximab soravtansine-gynx):
- Approved for the treatment of certain types of ovarian cancer, this drug is an antibody-drug conjugate (ADC) that targets the Folate Receptor Alpha (FRα). It is designed to deliver a potent cytotoxic agent directly to cancer cells that express FRα, thus sparing normal cells and reducing systemic toxicity.
2. AG-348:
- This investigational oral medication is under development for the treatment of individuals with PK deficiency. It is designed to restore normal red blood cell function by activating the glycolytic pathway, which is disrupted in patients with this rare genetic condition.
3. AG-636:
- An oral therapy in development aimed at treating various types of cancer. It targets mutant isocitrate dehydrogenase (IDH) enzymes found in certain cancers, including acute myeloid leukemia (AML) and glioma. The drug aims to inhibit these enzymes, which are integral to the altered metabolic pathways in cancer cells.
4. AG-221 (Ivosidenib):
- Approved for patients with IDH1-mutant relapsed or refractory AML, this targeted therapy works by inhibiting the IDH1 enzyme, which plays a role in tumorigenesis when mutated.
Services
- Clinical Development:
- Agios Pharmaceuticals is engaged in extensive clinical trials and studies to assess the safety and efficacy of its drug candidates. The company collaborates with healthcare institutions and partners to facilitate these trials, aiming to bring therapies from the lab to the patient.
- Regulatory Affairs:
- The company has a robust regulatory strategy to navigate the complex processes of obtaining approvals from regulatory bodies such as the FDA and EMA. This involves preparing submissions, responding to regulatory inquiries, and ensuring compliance with all regulatory requirements.
- Research and Development:
- Agios invests heavily in R&D to explore novel drug candidates and to understand disease mechanisms at the molecular level. Their focus on metabolic pathways provides a unique approach to drug discovery, particularly in oncology and rare diseases.
- Collaborative Partnerships:
- The company engages in partnerships with academic institutions and pharmaceutical companies to advance its therapeutic programs. These collaborations may encompass research agreements, co-development arrangements, and licensing deals that can enhance Agios’s drug pipeline and innovation.
With an integrated approach focusing on both rare diseases and cancers, Agios Pharmaceuticals continues to explore innovative therapeutic strategies, aiming to make a significant impact on patients with unmet medical needs.
Segments
1. Rare Genetic Diseases:
- Agios has a significant focus on rare genetic disorders, particularly those related to alterations in cellular metabolism. These disorders often require specialized treatments that target the underlying metabolic pathways. The companys pipeline includes therapies specifically aimed at treating conditions like pyruvate kinase deficiency (PK deficiency), which is a rare hereditary disease causing hemolytic anemia.
2. Oncology:
- The oncology segment involves the development of therapies aimed at various types of cancer. Agios is deeply invested in understanding the metabolic processes that drive cancer cell growth and survival, leading to the creation of targeted therapies that can selectively inhibit specific metabolic pathways that support tumor growth.
Products
1. Elahere (mirvetuximab soravtansine-gynx):
- Approved for the treatment of certain types of ovarian cancer, this drug is an antibody-drug conjugate (ADC) that targets the Folate Receptor Alpha (FRα). It is designed to deliver a potent cytotoxic agent directly to cancer cells that express FRα, thus sparing normal cells and reducing systemic toxicity.
2. AG-348:
- This investigational oral medication is under development for the treatment of individuals with PK deficiency. It is designed to restore normal red blood cell function by activating the glycolytic pathway, which is disrupted in patients with this rare genetic condition.
3. AG-636:
- An oral therapy in development aimed at treating various types of cancer. It targets mutant isocitrate dehydrogenase (IDH) enzymes found in certain cancers, including acute myeloid leukemia (AML) and glioma. The drug aims to inhibit these enzymes, which are integral to the altered metabolic pathways in cancer cells.
4. AG-221 (Ivosidenib):
- Approved for patients with IDH1-mutant relapsed or refractory AML, this targeted therapy works by inhibiting the IDH1 enzyme, which plays a role in tumorigenesis when mutated.
Services
- Clinical Development:
- Agios Pharmaceuticals is engaged in extensive clinical trials and studies to assess the safety and efficacy of its drug candidates. The company collaborates with healthcare institutions and partners to facilitate these trials, aiming to bring therapies from the lab to the patient.
- Regulatory Affairs:
- The company has a robust regulatory strategy to navigate the complex processes of obtaining approvals from regulatory bodies such as the FDA and EMA. This involves preparing submissions, responding to regulatory inquiries, and ensuring compliance with all regulatory requirements.
- Research and Development:
- Agios invests heavily in R&D to explore novel drug candidates and to understand disease mechanisms at the molecular level. Their focus on metabolic pathways provides a unique approach to drug discovery, particularly in oncology and rare diseases.
- Collaborative Partnerships:
- The company engages in partnerships with academic institutions and pharmaceutical companies to advance its therapeutic programs. These collaborations may encompass research agreements, co-development arrangements, and licensing deals that can enhance Agios’s drug pipeline and innovation.
With an integrated approach focusing on both rare diseases and cancers, Agios Pharmaceuticals continues to explore innovative therapeutic strategies, aiming to make a significant impact on patients with unmet medical needs.